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The two main goals of this chapter are: (a) to review the available Information 
on the importance of IL-1 for the synthesis of N G F and (b) to outline the most 
important gaps in our understanding of the mechanisms of this regulation. Topics 
discussed in the context of this second goal, such as release and processing of IL-
1, inhibitors and receptors (for brevity, activation of the IL-1 gene and its 
regulation will not be covered) are of general importance for the physiology and 
pathophysiology of EL-1 and thus overlap with other chapters of this volume is 
inevitable. 
10.1. Introduction to the physiology and pathophysiology of N G F 
and related neurotrophic molecules 
The neurotrophins form a family of proteins with established neurotrophic 
actions. At least three of its members have so far been identified and characterized 
in detail. NGF, which was discovered several decades ago (for a review of the 
history of this disco very, see Levi-Montalcini, 1987) is by far the best characterized 
of these molecules when compared to the more recently discovered brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) (for a short review, see 
Thoenen, 1991). A l l neurotrophins have arelated primary structure, as exemplified 
by the conservation of all six cysteine residues. However, certain regions of the 
molecule display sufficient structural variability to explain the different spectrum 
of neuronal specificity of each of these proteins. 
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In terms of biochemistry and physiology, N G F is the most well- known of these 
proteins and in this chapter it wil l suffice to introduce in more detail only N G F (for 
details and literature on B D N F and NT-3, see Thoenen, 1991). Under phy siological 
conditions the effects of N G F depend on the de velopmental stage of the responsi ve 
neurons (for extensive review of the physiology of NGF, see Levi-Montalcini and 
Angeletti, 1968; Thoenen and Barde, 1980; for an updated short review, see 
Barde, 1989). Düring the period of naturally occurring neuronal cell death, N G F 
regulates the extent of survival of specific populations of neurons (sympathetic 
and subpopulations of neural crest-derived primary sensory neurons)(see cited 
reviews; for a review on the survival of sensory neurons, see Johnson et a L , 1986) 
whereas in later developmental stages N G F mainly regulates specific neuronal 
properties; for example, N G F regulates the activity and synthesis of enzymes 
involved in neurotransmitter synthesis (i.e., tyrosine hydroxylase and choline 
acetyltransferase) and the synthesis of neuropeptides (for reviews, see Thoenen 
and Barde, 1980; Otten, 1984). Effects of N G F during the development of the 
CNS are less well-established. Administration of N G F prevents degeneration of 
cholinergic neurons of the basal forebrain after axotomy and improves the 
behavioural Performance of memory impaired aged rats (for recent reviews, see 
Thoenen e t a L , 1987; Whittemore and Seiger, 1987; Barde, 1989). N G F has also 
been shown to prevent neuronal degeneration after axotomy in the peripheral 
nervous System (Johnson et a L , 1985). Similar effects have been observed for the 
neurotrophins B D N F and NT-3 (see Thoenen, 1991). 
10.2. Macrophage-derived IL-1 upregulates NGF mRNA after 
lesion of a peripheral nerve 
After transsection of the rat sciatic nerve, a biphasic increase in N G F m R N A 
levels was observed in the nerve near the lesion site (Heumann et a L , 1987a). 
Directly distal and proximal to the lesion a first rapid increase of N G F m R N A 
occurred 6 hours after surgery attaining 25-30-fold augmented N G F m R N A 
levels. After a decrease to intermediate levels N G F m R N A reincreases to reach 
a second plateau phase 3-5 days after lesion. However, only the first rapid increase 
was observed in organ cultures of sciatic nerve. The addition of activated 
macrophages or medium conditioned by these cells to the organ cultures again 
results in an approximately 10-fold increase of N G F m R N A with maximum levels 
after 3-6 hours (Heumann et a L , 1987b). Of a variety of cytokines and growth 
factors which are synthesized by macrophages, recombinant human IL-1 (a or ß) 
has the strongest effects on N G F m R N A levels in nerve organ culture. This 
increase reaches its peak 3-6 hours after IL-1 addition and is maximal at 10 U/ml 
IL-1 ß. A smaller effect is seen with PDGF. Furthermore, neutralizing antibodies 
to IL-1 abolishes most of the N G F mRNA-inducing activity of macrophage-
conditioned media (Lindholm et a L , 1987). Taking into account the well-known 
invasion of macrophages to sites of peripheral nerve lesion (Beuche and Friede, 
1986; Stoll and Müller, 1986; Perry et a L , 1987) these findings are compatible 
with the following interpretation. Two to five days after lesion monocytes from 
the blood accumulate at the site of injury, become activated and release IL-1. This 
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protein then plays a major role in the upregulation of N G F m R N A in non-neuronal 
cells of the nerve sheath. By i n situ hybridization analysis of the distal and 
proximal nerve end, it has been shown that most non-neuronal cells of the nerve 
(including fibroblasts and Schwann cells) take part in the upregulation (Bandtlow 
et a L , 1987). Recently this interpretation received Support from observations 
made in mouse mutants in which macrophage invasion to the distal parts of 
lesioned nerves is absent (Lunn et a L , 1989; Brown et a L , 1991). This lack of 
macrophage invasion is correlated with a lowered expression of DL-1 ß m R N A in 
the distal nerve stump (Heumann et a L , 1990). In these mice the initial increase 
of N G F m R N A after transsection occurs, but the second is substantially reduced 
(Brown et a L , 1991). Accordingly, electrophysiological and morphological data 
show a strongly reduced regeneration of sensory fibres. This is in contrast to motor 
f ibres which regenerate at a normal rate and which (in contrast to sensory neurons) 
are not known to respond to N G F (Bisby and Chen, 1990; Brown et a L , 1991). 
Meanwhile, data on the expression of a second neurotrophin, BDNF, in the 
lesioned peripheral nerve are available. Under physiological conditions B D N F 
m R N A is predominantly expressed in the CNS (for literature, see Thoenen, 1991). 
Ho wever, after sciatic nerve lesion, high levels of B D N F m R N A are detected near 
the lesion site. The time-course of B D N F m R N A induction is rather slow 
compared to the increase of N G F m R N A after nerve lesion ( M . Meyer et a L , 
submitted). Additional evidence for a differential regulation of B D N F m R N A and 
N G F m R N A has been derived form nerve organ cultures, which under i n vitro 
conditions express intermediate levels of B D N F m R N A . They fail, however, to 
respond to IL-1 by an increase in B D N F m R N A ( M . Meyer et a L , submitted). 
Thus the expression of two members of a family of structurally closely related 
proteins is regulated in a differential way. This is interesting since neurons 
responsive to both proteins are present in dorsal root ganglia and extend their 
axons into the sciatic nerve. Therefore, it can be concluded that after nerve lesion, 
where a need for neurotrophic activity might be assumed, EL-1 does not act as a 
general inducer of all relevant neurotrophic proteins. In contrast, IL-1 seems to be 
a specific inducer of N G F m R N A . 
Analysis of the cellular targets of IL-1 in the nerve reveal that IL-1 acts in a cell 
type-specific manner, at least i n vitro. Primary fibroblasts cultured from the sciatic 
nerve respond to IL-1 by increasing N G F m R N A levels comparable in time-
course and magnitude to the response described for nerve organ cultures (Lindholm 
et a L , 1988). However, primary Schwann cells fail to upregulate N G F m R N A in 
response to IL-1 (Matsuoka et a L , 1991). We have evidence that Schwann cells 
display IL-1 binding sites (unpublished observations), and effects of EL-1 on the 
release of cultured Schwann cells of Plasminogen activator inhibitor have been 
published (Rogister et a L , 1990). Assuming that the interpretation of these data 
is correct, IL-1 can bind to Schwann cells and elicit effects different from 
induction of N G F m R N A . This apparent discrepancy leads to the following 
questions. First, other factors or cofactors (soluble and/or insoluble, such as cell-
contact molecules) present in the lesioned nerve, but not in the culture, might be 
required to increase N G F m R N A in Schwann cells. Second, dissociation and 
culturing of Schwann cells (but not fibroblasts or nerve explants taken from 
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newborn or adult animals; Matsuoka et a L , 1991) might selectively uncouple the 
DL-1 receptor from part of its intracellular signal transduction machinery, and thus 
disable N G F m R N A induction while maintaining other responses. Alternatively, 
Schwann cells might express two different types of EL-1 receptor, one of them 
being functionally upregulated only after nerve lesion. The type(s) of IL-1 
receptor expressed by Schwann cells has to await further analysis. 
A question already addressed in the preceding paragraph is whether the IL-1 
effects on N G F m R N A levels are mediated by other molecules. It has, for 
example, been shown that fibroblast proliferation observed after EL-1 application 
depends on DL-1 induced secretion of P D G F (Raines e t a L , 1989). Furthermore, 
in the CNS some effects of EL-1 are apparently mediated by C R F secretion (see 
Rothwell, 1990). However, P D G F (AB or B B dimer) does not increase N G F 
m R N A levels in cultured Schwann cells (Matsuoka e t a L , in press) although they 
express the appropriate P D G F receptor (Weinmaster and Lemke, 1990). Recently, 
a variety of growth factors and signal transduction pathways have been analysed 
for their influence on N G F m R N A levels in cultured Schwann cells (Matsuoka et 
al, 1991). Whereas all peptide growth factors tested so far failed to augment N G F 
m R N A levels, elevation of intracellular c A M P results in a rapid (maximum after 
3-6 hours) elevation of N G F m R N A (6-8 fold) which can be further increased 
by coadministration of ionomycin and/orTPA. However, the extracellular Signals 
which might trigger these pathways in pathophysiological situations are still 
elusive. 
10.3. Possible role of IL-1 for the physiological regulation of NGF 
mRNA levels in the central nervous System 
10.3.1. Localization and function of IL-1 in the brain 
In view of the reports that cultured astrocytes (Fontana et a L , 1982) and 
microglial cells (Giulian et a L , 1988; Hetier et a L , 1988; Gebicke-Haerter et a L , 
1989) can express IL-1 we questioned whether this protein is produced and might 
be involved in the regulation of N G F m R N A levels in the intact brain. Consequently, 
using i n situ hybridization, the localization of N G F and IL- lß transcripts 
throughout the adult rat brain was analysed (Bandtlow et a L , 1990). Several 
interesting features of EL-1 ß m R N A expression in the brain were revealed. First, 
there is indeed aco-localization of N G F m R N A and IL-1 ß m R N A in most regions 
(periglomerular cell layer in the olfactory bulb, frontal cortex, pyramidal cell 
layer of the hippocampus, granule cell layer of the dentate gyrus), with some 
exceptions. IL-1 ß m R N A , but not N G F m R N A , was detected in the granule cell 
layer of the cerebellum, parts of the hypothalamus and the internal granulär layer 
of the olfactory bulb. Limits in the sensitivity of the i n situ analysis may explain 
some of these exceptions. Of course, this co-localization does not prove a causal 
relationship between DL-1 and N G F synthesis. Second, expression is mostly 
neuronal. Silver grains are found more or less exclusively over granule cells of 
dentate gyrus and cerebellum (but not over Purkinje cells of the cerebellum); 
periglomerular cells in the olfactory bulb; and neurons in the frontal cortex. Third, 
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the level of expression differs markedly between neurons in the same region (with 
one exception). This was not true for cerebellar granule cells which showed a 
rather homogenous labelling pattern. A similar pattern has been described, for 
example, for the expression in the brain of mRNAs encoding neurotrophins some 
of which have been shown to be regulated by neuronal activity (for literature, see 
Zafra etal, 1990). In contrast, other mRNAs, such as P D G F - A m R N A ( Y e h e t a L , 
1991) show approximately equal levels of expression in all neurons of a specific 
brain region. This might suggest that neuronal activity also plays a role in the 
expression of IL - lß m R N A levels in contrast to, for example, P D G F A-chain 
m R N A levels. Direct evidence for this type of regulation has recently been 
provided. After kainic acid-induced convulsion a rapid upregulation of IL - lß 
m R N A has been observed in cerebral cortex, hypothalamus and hippocampus 
(but not in the cerebellum) (Minami et a L , 1991). 
Our findings are in general agreement with data from other groups. Farrar et 
aL( 1987) described the detection of IL-1 ß m R N A by i n situ hybridization in the 
dentate gyrus and the pyramidal cell layer of the hippocampus. In contrast to their 
report, we did not see any signal over the choroid plexus. Lechan et a/.(1990) 
found IL - lß immunoreactivity in processes of granule cells in the rat dentate 
gyrus. Brederefa/.( 1988) and Lechan e t a l . ( 1990) described EL-1 immunoreactivity 
in the hypothalamus of human and rat, respectively. Using Polymerase chain 
reaction methods for the detection of IL - lß m R N A Higgins et a L (1991) 
confirmed the presence of very low levels of this m R N A in the intact rat brain. 
Using similar methods, Minami et a L (1991) detected low levels of EL-1 ß m R N A 
in a variety of brain regions, including cerebral cortex, hippocampus, hypothalamus 
and cerebellum. 
A l l of these investigations have been performed in adult animals and data on 
the developmental expression of IL-1 in the brain, spinal cord and PNS are still 
lacking. A comparison of data on the expression of IL-1 and N G F during the 
development of the nervous System might further strengthen the hypothesis of a 
causal relationship between IL-1 and N G F synthesis. 
Although substantial information on the regional distribution of IL-1 in the 
brain is available, little is known about the physiological function of endogenous 
IL-1. Intraventricular administration of IL- lß results in increased N G F m R N A 
levels in the surrounding brain tissue (Spranger et a L , 1990), but this does not 
necessarily reflect the effects of physiological concentrations of IL-1 in the non-
lesioned brain. So far, there is no direct proof for a causal relationship between the 
synthesis of IL-1 and NGF. Furthermore, considering recent work on the influence 
of neuronal activity on the regulation of N G F m R N A and B D N F m R N A in the 
brain (see Zafra et a L , 1990) it is evident that IL-1 is only one regulator of N G F 
m R N A synthesis among others. The roles of these different regulatory mechanisms 
for physiological and pathophysiological processes remain to be investigated. 
Outside the nervous System DL-1 is well-established as amediator of pathological, 
mostly inflammatory reactions (for reviews see Martin and Resch, 1988; Dinarello 
and Endres, 1989; Schmidt and Tocci, 1990). What is its role (if any) in brain 
pathology? 
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Interleukin-1-like activity has been shown to accumulate in brain wounds 
(Nieto-Sampedro and Berman, 1987), but its source, in particular whether it is 
derived from within the brain parenchyma or produced by blood cells, has not 
been analysed. The presence of IL-1 ß m R N A and IL-1 immunoreactivity has been 
reported in the brain of Alzheimer patients (Griffin et a L , 1989; Rogers et a L , 
1980; but see also Hofman et a L , 1986) and patients suffering from multiple 
sclerosis (Hofman et a L , 1986). Thus, IL-1 expression is modulated in pathological 
states of the brain. Whether this disease-induced DL-1 expression plays a role for 
restoration of brain function or, also possible, for maintenance of disease, remains 
to be elucidated. 
In the f ollowing, some of the prerequisites for the action of IL-1 in the brain wil l 
be discussed. These include processes necessary for the generation of bioactive 
IL-1 (processing and release), the control of availability of DL-1 for target cells 
(inhibitors) and the regulation of EL-1 receptor expression. 
10.3.2. Expression of the IL-1 receptor 
The effects of IL-1 are mediated via cell surface receptors and a co-distribution 
of EL-1 and IL-1 receptor expression is a prerequisite of autocrine or paracrine IL-
1 function in a particular brain region. Specific binding of iodinated IL-1 has been 
demonstrated in an autoradiographic study by Farrar et a/.(1987) in the dentate 
gyrus, hippocampal pyramidal cell layer, hypothalamus and cerebellar granule 
cells. More recent autoradiographic studies by Haour et aL (1990 and this volume) 
and Takao et a L (1990) confirmed the binding in the dentate gyrus, but were 
unable to demonstrate further binding sites. Consistent with the autoradiographic 
data, Wada et a L (1990) in an i n situ study, localized the m R N A coding for the 
type-1 IL-1 receptor in the dentate gyrus. Takao et a L (1990) demonstrated 
additional binding sites in membrane fractions derived from cerebral cortex and 
olfactory bulb. If this is interpreted as binding to neurons, the data on localization 
ofIL-1 and IL-1 receptor expression suggest that EL-1 acts in an autocrine manner. 
However, considering the well-known endocrinological and metabolic effects of 
EL-1 (see the relevant chapters in this volume) it is still surprising that, besides 
Farrar et a L (1987), no other group has been able to reveal autoradiographically 
detectable binding sites for IL-1 in the hypothalamus. Either receptor density in 
this region (in contrast to the dentate gyrus of the hippocampus) is at the limits of 
sensitivity of the method or these effects of IL-1 are mediated via other brain 
regions. 
Moreover, regulation of receptor expression and function might represent an 
important f eature of the regulation of the response of the brain to EL-1 (see chapter 
by F. Haour, this volume). From the periphery (lymphocytes) it is known, for 
example, that glucorticoids upregulate the number of high-affinity EL-1 receptors 
(Akahoshi et a L , 1988). Since glucocorticoid receptors are widely expressed in 
the brain (see Arriza et a L , 1988) these regulatory mechanisms, if present in the 
brain, could be of relevance to the action of IL-1 in the normal and pathologic 
brain. In contrast to glucocorticoids, transforming growth factor ß is a potent 
inhibitor of IL-1 receptor expression on lymphoid cells (Dubois et a L , 1990). 
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Synthesis of TGFß m R N A has been demonstrated in the normal and lesioned 
brain (Nichols etat, 1991; Lindholm etat, unpublished). 
10.3.3. Processing and release of IL-1 
The release and processing of interleukin-1 might be another step where the 
action of IL-1 can be controlled. Both E L - l a and EL- lß are synthesized as 
precursor molecules without recognizable signal peptide (Lomedico et a L , 1984; 
Auron et a L , 1984; March et a L , 1985). In spite of these structural peculiarities, 
several studies on the kinetics of intracellular and extracellular accumulation of 
EL-1 have demonstrated that this protein can indeed be released from intact cells. 
This is particularly well-established for monocytes and macrophages (Giri e t a L , 
1985; Auron et a L , 1987; Hazuda et a L , 1988). Studies analysing the electron- or 
light-microscopic distribution of EL-1 in the cell, as well as those using subcellular 
fractionation techniques, localized the protein outside the compartments of the 
classical secretory pathway via endoplasmic reticulum and Golgi apparatus 
(Bayneefa/., 1986;Matsushimaefa/., 1986;Conlonefa/., 1987;Bakoucheefa/., 
1987; Singer et a L , 1988; Baldari et a L , 1989; Beesley et a L , 1990; Rubartelli et 
a L , 1990). Furthermore, although human EL-1 ß contains N-glycosylation consensus 
sequences EL-1 ß released by human macrophages is not glycosylated. However, 
if human IL-1 ß is expressed with an aminoterminal extension coding for a known 
signal peptide itbecomes N-glycosylated (Baldari e t a L , 1987, L i v i e t a L 1991). 
This demonstrates again that IL-1 ß does not normally reach compartments where 
N-glycosylation takes place. For macrophages and monocyte cell lines it has 
recently been demonstrated that IL-1 might be released after uptake into a not yet 
characterized membrane-confined compartment (Rubartelli et a L , 1990). How 
this is achieved is not clear, but recent work suggests that also in eukaryotic cells, 
a special family of transporter proteins related to mammalian drug resistance gene 
products, helps to translocate proteins between different intracellular compartments. 
This is particularly well-established for yeast where the release of a small peptide, 
the pheromone a-factor, depends on the expression of a gene (STE6) coding for 
one of these putative transporter proteins (Kuchler et a L , 1989; McGrath et a L , 
1989). A related translocation pathway apparently plays a role for the intracellular 
sorting of antigenic peptides (for an overview see, Parham, 1990). In contradiction 
to release mechanisms which allow survival of the EL-1 producing cells, recent 
work by Hogquist et a L (1991) demonstrates that IL-1 release from macrophages 
and its processing are correlated to apoptotic cell death. 
Processing of IL-1 from the precursor to the mature form seems to occur 
simultaneously with its release. It has been demonstrated at least for human IL-
1 ß that processing is necessary for füll bioactivity and thus the regulation of 
processing mightrepresentanotherpost-translational controlmechanism (Mosley 
et a L , 1987; Beuscher et a L , 1990). The enzymes required for processing are not 
ubiquitously expressed since fibroblasts transfected with c D N A s encoding the 
precursors of IL-1 oc or IL-1 ß (Fuhlbrigge et a L , 1988; Young et a L , 1988) failed 
to produce and release mature EL-1. Moreover, distinct proteases have been 
identified which can generate the mature forms of IL-1 oc (Kobayashi et a L , 1990) 
and IL- lß (Black et a L , 1989a; b; Kostura et a L , 1989, Howard et a L , 1991). 
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10.3.4. Inhibitors of IL-1 
After release the action of EL-1 can be controlled by degradation and by IL-1 
binding proteins and by IL-1 receptor antagonists. Whereas nothing is known 
about mechanisms of IL-1 degradation in peripheral Organs or in the nervous 
System, a variety of IL-1 binding proteins and IL-1 inhibitors have been described 
(for a review on IL-1 inhibitors, see Larrick et a L , 1989). There is evidence that 
some of these binding proteins represent extracellular parts of the EL-1 receptors 
(Giri et a L , 1990; Eastgate et a L , 1990). Some of these binding proteins are 
specific for one form of IL-1 (in this case for EL-lß) and might regulate the 
differential availability of IL-1 isoforms. Surprising was the discovery of IL-1 
receptor antagonists which are structurally related to IL-1 (but in contrast to IL-
1 may contain an N-terminal signal peptide) and act as competitive antagonists of 
EL-1 at the type-I receptor (Bienkowski et a L , 1990; Eisenberg et a L , 1990; 
Hannumera/., 1990; Carter e t a L , 1990;Mazzeiefa/., 1990;Haskillera/., 1991). 
It remains to be investigated whether and where these inhibitors or receptor 
antagonists are expresssed in the nervous System. 
10.4. A second endogenous source of IL-1 might play a role during 
the first phase of NGF mRNA induction after peripheral nerve 
lesion 
As described abo ve, we belie ve that the second phase of N G F m R N A induction 
after peripheral nerve lesion is due to IL-1 released from invading macrophages. 
But what are the Signals and the mechanisms responsible for the first, rapid and 
transient, increase? 
The time-course of first phase and its pharmacological characteristics (Lindholm 
et a L , 1988) together with the demonstration of IL-1 in neurons (see previous 
Paragraph; Schultzberg et a L , 1987) suggested that this phase might also be 
caused by EL-1 synthesized in the nerve. Therefore we analysed the content of the 
sciatic nerve for N G F mRNA-inducing activity. Indeed, under experimental 
conditions which exclude protein synthesis, a strong N G F mRNA-inducing 
activity was detected. Furthermore, adsorption with polyclonal antibodies directed 
against the N-terminal end of rat IL - lß removed between 40-60% of this N G F 
mRNA-inducing activity (unpublished observations). These experiments show, 
first, that preformed factors present in the nerve might play a role for the 
upregulation of N G F m R N A after nerve lesion, and, second, that approximately 
half of this activity is IL- lß . Thus, in the peripheral nervous System I L - l ß and 
some as yet unknown molecules act as lesion factors which are released after 
trauma. It remains to be seen where these lesion factors are stored in the intact 
nerve and whether they are stored in an active or inactive form which is processed 
during the degenerative process. We do not yet know whether I L - l a which has 
been detected in the peripheral nervous System (Schultzberg et a L , 1987 and this 
volume) plays a role in this context. 
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10.5. Conclusions 
IL-1 is a potent regulator of many diverse processes in the central and 
peripheral nervous System including N G F m R N A upregulation in the lesioned 
peripheral nerve. Endogenous, mainly neuronal, expression of IL-1 ß m R N A and 
IL-1 activity has been discovered in the normal C N S . Data on the localization of 
N G F m R N A and EL-lb m R N A , and IL-1 receptor expression suggest that 
endogenous IL-1 might play a role in the physiological regulation of N G F 
expression in the C N S . 
Many aspects of the regulation of IL-1 action in the nervous System have not 
yet been investigated. Analysis of the regulation of IL-1 m R N A expression in 
neural tissues and cells might be a rapid way to suggest possible roles for IL-1 in 
the normal brain and in brain pathology. However, due to the particular post-
transcriptional and post-translational events necessary for the generation of active 
IL-1 (release, processing) attention has to be focused on the active protein. 
Furthermore, even after release of active protein many players can modulate the 
effects of IL-1 (degradation, binding proteins, receptor antagonists, receptor 
expression and coupling to signal transduction pathways). 
Thus, IL-1, its function and the control of its action in the brain and in the PNS 
remain very attractive topics for future research. 
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